Arcutis outlines $535M-$545M 2026 net revenue guidance while preparing for February 23, 2027 infant AD PDUFA (NASDAQ:ARQT)

Arcutis Biotherapeutics (ARQT) reported Q3 2026 net product revenues of $143.9M, citing strong sales and demand growth. The company outlined 2026 net revenue guidance of $535M-$545M and is preparing for a February 23, 2027 PDUFA date for its infant AD treatment, according to CEO Todd Watanabe.

Original reporting
Published Nov 5, 2026, 4:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 4:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARQT
Bearish
high confidence
Mentioned
$ARQT
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ARQTBearishHigh
01

Why it matters

The guidance range of $535M-$545M is a key data point for valuation models.

02

Market read

New revenue guidance is material for traders and may drive short-term price movement.

03

What to watch

Potential upcoming regulatory approvals or pipeline milestones not mentioned.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Arcutis Biotherapeutics (NASDAQ:ARQT) reported Q3 product revenue and provided 2026 guidance.

Company-level read

Ticker impact

$ARQTBearishHigh confidence
Context

Arcutis disclosed Q3 net product revenues of $143.9M and set 2026 net revenue guidance of $535M-$545M.

Expected impact

potential downside as investors price in lower revenue outlook

Evidence & confidence

New guidance numbers are material and were not previously public, likely prompting a sell pressure.

Market effects

Biotech sector may see broader sentiment shift if guidance trends repeat.

US biotech investors likely adjust positions.

Limited to firms with similar product pipelines.

Counterpoint

Guidance could be a buying opportunity if the market overreacts to short-term numbers.

Key entities

  • Arcutis Biotherapeutics

    Biopharma developing dermatology treatments.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.